Skip to content

Comparative evaluation of teraputic effects (improving indicators) related to Recurrent HerpesLabialis using Nano and mocoadhesive formulation of acyclovir and acyclovir_clobetasole

Comparative evaluation of teraputic effects (improving indicators) related to Recurrent HerpesLabialis using Nano and mocoadhesive formulation of acyclovir and acyclovir_clobetasole

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
IRCT
Registry ID
IRCT20230926059521N1
Enrollment
80
Registered
2023-11-14
Start date
2017-08-23
Completion date
Unknown
Last updated
2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recurrent herpes labialis.

Interventions

Intervention group: 80 patients with recurrent labial herpes.

Sponsors

Esfahan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: (The lesion is recurrent (secondary) and not primary in any case. 2) The age range of the patient should be between 18 and 60 years. does not. 5) The patient should not use any lip moisturizing topical cosmetics or sun cream in the lesion area during the treatment, and should not perform any manipulations such as scratching or facial modification in the area. 6) The lesion should be in the papule-vesicle stage

Exclusion criteria

Exclusion criteria: Having an allergy to acyclovir or a history of severe allergy to other drugs. 2) Using topical or systemic drugs to treat recurrent herpes labialis in the last 4 weeks. 3) Suffering from systemic diseases or liver and kidney failure diseases. 4) Using Contraceptive pills and breastfeeding. 5) suffering from immunodeficiency and acquired diseases

Design outcomes

Primary

MeasureTime frame
The amount of pain or burning was calculated and recorded by the patient with a score scale, and the time of dressing the scab and recovery time was recorded by the clinician. Timepoint: 1st to 7th day after delivery of medicine. Method of measurement: The amount of pain or burning was calculated and recorded by the patient with a score scale, and the time of dressing the scab and recovery time was recorded by the clinician.

Countries

Iran (Islamic Republic of)

Contacts

Public Contactsolmazmohamadi

Esfahan University of Medical Sciences

solmazmohamadi.dnt2@gmail.com038332225243

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 5, 2026